Recursion Pharmaceuticals Announces New Clinical Data Readout for REC-4881 in Familial Adenomatous Polyposis
I'm PortAI, I can summarize articles.
Recursion Pharmaceuticals will present new clinical data from the TUPELO Phase 1b/2 trial of REC-4881 for Familial Adenomatous Polyposis on December 8, 2025. The webinar will include safety and efficacy results, featuring presentations by company leaders and external experts. The results have not been disclosed yet.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments